Important HIV Prevention, Treatment and Cure Research Unveiled at AIDS 2020
Important HIV Prevention, Treatment and Cure Research Unveiled at AIDS 2020
Leading HIV researchers announced important new developments
in HIV research at the 23rd International AIDS Conference (AIDS 2020: Virtual)
held recently. This includes what could also be the primary report of an adult
with HIV to realize long-term HIV remission without the necessity for a bone
marrow transplant and new data showing that long-acting injectable cabotegravir
is superior to daily oral Truvada for pre-exposure prophylaxis (PrEP).
Other announcements included promising new insights on
PrEP's impact on reducing HIV incidence in rural Kenya and Uganda, encouraging
data on the potential link between dolutegravir and ectoderm defects, and
positive leads to an attempt comparing multidrug antiretroviral therapies.
"Since 1985 the International AIDS Conference has
helped answer the foremost pressing research questions in HIV, and this year is
not any different," Anton Pozniak, President of the International AIDS
Society and International Chair of AIDS 2020: Virtual, said. "The studies
presented at AIDS 2020: Virtual advance our knowledge on multiple fronts,
knowledge which will potentially help the communities and regions most impacted
by HIV worldwide."
No comments